Paratek Pharmaceuticals Presenting New Data from NUZYRA® (Omadacycline) and Investigator-Initiated Pre-Clinical Studies at ESCMID Global (Formerly ECCMID)
-- Third procurement to be split into two procurements based on the achievement of specific anthrax development milestones-- Next procurement expected in early 2024 BOSTON, July 10, 2023 (GLOBE...
BOSTON, June 27, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
BOSTON, June 12, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
BOSTON, April 10, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government and military use, today announces that new data from studies with NUZYRA® (omadacycline) will be presented at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID). nnThe hybrid conference will be held April 15-18 at the Bella Center Copenhagen in Copenhagen, Denmark. View ECCMID scientific program here. nn“We continue to generate new data to enhance understanding of NUZYRA’s utility, both to enhance clinicians’ confidence in prescribing it for patients with life-threatening, community-acquired infections as well as to explore its potential to address additional unmet needs,” said Randy Brenner, chief development and regulatory officer of Paratek. “Accordingly, poster presentations at ECCMID feature a wide range of new research exploring effects of NUZYRA, including on microbiome diversity, against multi-drug resistant pathogens, in vitro activity against infrequently encountered bacterial pathogens, and the durability and safety of NUZYRA in nontuberculous mycobacteria (NTM) from a retrospective analysis.”
Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of...
Paratek Pharmaceuticals Announces Positive Top Line Data from Pilot Efficacy Study for the Treatment of Pulmonary Anthrax and Acceptance of the Second Procurement of NUZYRA® (omadacycline) under BARDA Project BioShield
Paratek Pharmaceuticals, Inc. announced the commercial availability of U.S.-produced NUZYRA (omadacycline) tablets. This milestone follows a successful technology transfer by Paratek and its tablet manufacturing partners in the U.S. and Europe.
BOSTON, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today announces that new data from the NUZYRA® (omadacycline) non-clinical and investigator-initiated research programs will be presented at IDWeek 2022.
Lyon, France - February 15, 2022 – Novasep, a leading supplier of services and technologies for the life sciences industry, and Paratek Pharmaceuticals, a commercial-stage biopharmaceutical company, have signed an agreement to ramp up the commercial production of omadacycline, the Active Pharmaceutical Ingredient (API) used for NUZYRA® (omadacycline), an FDA-approved tetracycline-class, once-daily oral and intravenous antibiotic for the treatment of adults with community-acquired bacterial pneumonia (CABP) and acute bacterial skin and skin structure infections (ABSSSI).